Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.46
NAS:TECH's Cash-to-Debt is ranked lower than
92% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:TECH: 0.46 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:TECH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.46  Med: 28.07 Max: No Debt
Current: 0.46
Equity-to-Asset 0.61
NAS:TECH's Equity-to-Asset is ranked lower than
60% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:TECH: 0.61 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:TECH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.88 Max: 0.97
Current: 0.61
0.51
0.97
Debt-to-Equity 0.36
NAS:TECH's Debt-to-Equity is ranked lower than
61% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:TECH: 0.36 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:TECH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.11 Max: 0.36
Current: 0.36
0.02
0.36
Interest Coverage 16.38
NAS:TECH's Interest Coverage is ranked lower than
80% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:TECH: 16.38 )
Ranked among companies with meaningful Interest Coverage only.
NAS:TECH' s Interest Coverage Range Over the Past 10 Years
Min: 16.38  Med: No Debt Max: No Debt
Current: 16.38
Piotroski F-Score: 4
Altman Z-Score: 5.98
Beneish M-Score: -2.94
WACC vs ROIC
7.07%
7.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 21.42
NAS:TECH's Operating Margin % is ranked higher than
88% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:TECH: 21.42 )
Ranked among companies with meaningful Operating Margin % only.
NAS:TECH' s Operating Margin % Range Over the Past 10 Years
Min: 21.42  Med: 51.93 Max: 58.1
Current: 21.42
21.42
58.1
Net Margin % 13.51
NAS:TECH's Net Margin % is ranked higher than
84% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:TECH: 13.51 )
Ranked among companies with meaningful Net Margin % only.
NAS:TECH' s Net Margin % Range Over the Past 10 Years
Min: 13.51  Med: 35.98 Max: 40.8
Current: 13.51
13.51
40.8
ROE % 8.41
NAS:TECH's ROE % is ranked higher than
85% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:TECH: 8.41 )
Ranked among companies with meaningful ROE % only.
NAS:TECH' s ROE % Range Over the Past 10 Years
Min: 8.32  Med: 16.88 Max: 22.91
Current: 8.41
8.32
22.91
ROA % 5.24
NAS:TECH's ROA % is ranked higher than
85% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:TECH: 5.24 )
Ranked among companies with meaningful ROA % only.
NAS:TECH' s ROA % Range Over the Past 10 Years
Min: 5.24  Med: 15.92 Max: 22.16
Current: 5.24
5.24
22.16
ROC (Joel Greenblatt) % 57.40
NAS:TECH's ROC (Joel Greenblatt) % is ranked higher than
91% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:TECH: 57.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:TECH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 55.51  Med: 107.67 Max: 112.73
Current: 57.4
55.51
112.73
3-Year Revenue Growth Rate 15.80
NAS:TECH's 3-Year Revenue Growth Rate is ranked higher than
69% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:TECH: 15.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:TECH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.3  Med: 13.1 Max: 23
Current: 15.8
5.3
23
3-Year EBITDA Growth Rate -0.70
NAS:TECH's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:TECH: -0.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:TECH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -0.7  Med: 15.65 Max: 67
Current: -0.7
-0.7
67
3-Year EPS without NRI Growth Rate -12.20
NAS:TECH's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:TECH: -12.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:TECH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -12.2  Med: 19.45 Max: 58.7
Current: -12.2
-12.2
58.7
GuruFocus has detected 7 Warning Signs with Bio-Techne Corp $NAS:TECH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:TECH's 30-Y Financials

Financials (Next Earnings Date: 2017-10-31 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

TECH Guru Trades in Q3 2016

Jim Simons 143,500 sh (+260.55%)
Mairs and Power 1,367,099 sh (+1.17%)
Paul Tudor Jones Sold Out
Ron Baron 1,636,421 sh (-0.35%)
Chuck Royce 741,359 sh (-3.25%)
Columbia Wanger 611,536 sh (-15.82%)
» More
Q4 2016

TECH Guru Trades in Q4 2016

Jim Simons 181,500 sh (+26.48%)
Chuck Royce 775,259 sh (+4.57%)
Mairs and Power 1,368,650 sh (+0.11%)
Ron Baron 1,600,092 sh (-2.22%)
Columbia Wanger 589,563 sh (-3.59%)
» More
Q1 2017

TECH Guru Trades in Q1 2017

Jim Simons 188,600 sh (+3.91%)
Chuck Royce 804,859 sh (+3.82%)
Mairs and Power 1,389,850 sh (+1.55%)
Ron Baron 1,513,617 sh (-5.40%)
Columbia Wanger 243,389 sh (-58.72%)
» More
Q2 2017

TECH Guru Trades in Q2 2017

George Soros 2,000 sh (New)
Ray Dalio 4,878 sh (New)
Mairs and Power 1,448,987 sh (+4.25%)
Ron Baron 1,499,942 sh (-0.90%)
Chuck Royce 730,359 sh (-9.26%)
Jim Simons 147,100 sh (-22.00%)
Columbia Wanger 176,486 sh (-27.49%)
» More
» Details

Insider Trades

Latest Guru Trades with TECH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2017-06-30 Reduce -0.90%0.01%$99.28 - $118.76 $ 121.9012%1,499,942
George Soros 2017-06-30 New Buy0.01%$99.28 - $118.76 $ 121.9012%2,000
Ron Baron 2017-03-31 Reduce -5.40%0.05%$97.9 - $108.2 $ 121.9018%1,513,617
Ron Baron 2016-12-31 Reduce -2.22%0.02%$99.28 - $111.17 $ 121.9016%1,600,092
Ron Baron 2016-09-30 Reduce -0.35%$104.5 - $115.17 $ 121.9011%1,636,421
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:ACAD, NAS:JUNO, NAS:NBIX, NAS:UTHR, NAS:PBYI, NAS:FGEN, NAS:NKTR, NAS:CLVS, NAS:AGIO, NAS:PTLA, NAS:BIVV, NAS:BLUE, NAS:ONCE, NAS:SRPT, NAS:LGND, NAS:AVXS, NAS:TSRO, NAS:LOXO, NAS:ICPT, NAS:RARE » details
Traded in other countries:TE1.Germany,
Headquarter Location:USA
Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products.

Bio-Techne is a biotechnology company that develops, manufactures, and sells biotechnology products for research and clinical diagnostic markets worldwide. Bio-Techne develops specialized proteins, including cytokines and growth factors, antibodies, related immunoassays, biologically-active small molecules, and other reagents, as well as instrumentation designed to simplify key protein analysis processes. The company also serves the clinical markets with regulated products such as controls, calibrators, reagents, and immunoassays intended for diagnostic uses.

Guru Investment Theses on Bio-Techne Corp

Baron Funds Comments on Bio-Techne Corp - Nov 02, 2015

Bio-Techne Corporation (NASDAQ:TECH) sells specialized proteins, antibodies and other reagents, as well as instruments for protein analysis, to life sciences researchers at academic institutions, biopharmaceutical companies and government-funded research entities. Its products are used by scientists to investigate potential therapies for disease. Most of the company’s products are for research purposes only, and so they avoid the need for expensive, time-consuming regulatory approvals. The products are also relatively inexpensive, and they generally do not represent large cost items in most clients’ research budgets. With a portfolio of more than 275,000 products, Bio-Techne has by far the largest portfolio in its field, making the company a key supplier across its customer base.





We have also owned this stock in Baron Growth Fund for many years. We believe that Bio-Techne has attractive financial characteristics, including consistent revenue growth potential, high profit margins potential, and low capital requirements. We also believe the company has a reputation for manufacturing high quality, reliable, consistent products. The company has a staff of scientists who stay current with scientific advances and areas of interest for researchers and help direct product development into these growing areas.





Starting in 2010, the company’s organic growth slowed to the low single digits because of academic funding constraints, which hurt customer spending, and a lack of re-investments in the business by the former management team. Chuck Kummeth, who assumed the CEO position in April 2013, has been taking steps to reinvigorate growth, including hiring new executives and salespeople, making acquisitions, and expanding in China where the government is committed to investing in life sciences research.





We bought the stock in the quarter because we believe the fundamentals of this attractive business will continue to improve. In the most recently reported quarter, organic growth accelerated to 7%, the highest level in years. The funding environment for the company’s customer base is stable. Drug development budgets are improving. There have been proposed increases in the NIH budget, though uncertainty about the final budget remains. The company is annualizing the acquisition of a business called Protein Simple, which we believe has potential to drive revenue growth acceleration through the sale of its innovative instrument platform that automates the Western Blotting technique. Management has an aspirational plan to grow the company’s revenues to $1 billion in the next five years. Despite improving fundamentals, the stock price trades at what we believe is an attractive level.



From the Baron Asset Fund shareholder letter Q3 2015 by Andrew Peck.



Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 60.06
TECH's PE Ratio is ranked lower than
77% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. TECH: 60.06 )
Ranked among companies with meaningful PE Ratio only.
TECH' s PE Ratio Range Over the Past 10 Years
Min: 16.78  Med: 27.5 Max: 60.62
Current: 60.06
16.78
60.62
Forward PE Ratio 29.59
TECH's Forward PE Ratio is ranked lower than
74% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. TECH: 29.59 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 60.06
TECH's PE Ratio without NRI is ranked lower than
76% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. TECH: 60.06 )
Ranked among companies with meaningful PE Ratio without NRI only.
TECH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 16.78  Med: 27.5 Max: 60.62
Current: 60.06
16.78
60.62
Price-to-Owner-Earnings 43.24
TECH's Price-to-Owner-Earnings is ranked lower than
60% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. TECH: 43.24 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TECH' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 17.03  Med: 26.82 Max: 49.6
Current: 43.24
17.03
49.6
PB Ratio 4.80
TECH's PB Ratio is ranked lower than
58% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. TECH: 4.80 )
Ranked among companies with meaningful PB Ratio only.
TECH' s PB Ratio Range Over the Past 10 Years
Min: 3.27  Med: 4.48 Max: 6.5
Current: 4.8
3.27
6.5
PS Ratio 8.13
TECH's PS Ratio is ranked higher than
58% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. TECH: 8.13 )
Ranked among companies with meaningful PS Ratio only.
TECH' s PS Ratio Range Over the Past 10 Years
Min: 6.63  Med: 8.75 Max: 12.48
Current: 8.13
6.63
12.48
Price-to-Free-Cash-Flow 35.63
TECH's Price-to-Free-Cash-Flow is ranked lower than
62% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. TECH: 35.63 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TECH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 17.68  Med: 26.94 Max: 35.97
Current: 35.63
17.68
35.97
Price-to-Operating-Cash-Flow 31.87
TECH's Price-to-Operating-Cash-Flow is ranked lower than
65% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. TECH: 31.87 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TECH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 15.74  Med: 23.93 Max: 32.35
Current: 31.87
15.74
32.35
EV-to-EBIT 39.76
TECH's EV-to-EBIT is ranked lower than
75% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. TECH: 39.76 )
Ranked among companies with meaningful EV-to-EBIT only.
TECH' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.4  Med: 17.3 Max: 40.3
Current: 39.76
10.4
40.3
EV-to-EBITDA 26.45
TECH's EV-to-EBITDA is ranked lower than
63% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. TECH: 26.45 )
Ranked among companies with meaningful EV-to-EBITDA only.
TECH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.9  Med: 16.3 Max: 26.8
Current: 26.45
9.9
26.8
EV-to-Revenue 8.44
TECH's EV-to-Revenue is ranked higher than
60% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. TECH: 8.44 )
Ranked among companies with meaningful EV-to-Revenue only.
TECH' s EV-to-Revenue Range Over the Past 10 Years
Min: 6  Med: 8.3 Max: 11.5
Current: 8.44
6
11.5
PEG Ratio 74.88
TECH's PEG Ratio is ranked lower than
97% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. TECH: 74.88 )
Ranked among companies with meaningful PEG Ratio only.
TECH' s PEG Ratio Range Over the Past 10 Years
Min: 1.09  Med: 3.15 Max: 104.52
Current: 74.88
1.09
104.52
Shiller PE Ratio 40.16
TECH's Shiller PE Ratio is ranked higher than
57% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. TECH: 40.16 )
Ranked among companies with meaningful Shiller PE Ratio only.
TECH' s Shiller PE Ratio Range Over the Past 10 Years
Min: 24.39  Med: 33.89 Max: 56.47
Current: 40.16
24.39
56.47
Current Ratio 2.57
TECH's Current Ratio is ranked lower than
73% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. TECH: 2.57 )
Ranked among companies with meaningful Current Ratio only.
TECH' s Current Ratio Range Over the Past 10 Years
Min: 2.57  Med: 7.91 Max: 17.79
Current: 2.57
2.57
17.79
Quick Ratio 2.12
TECH's Quick Ratio is ranked lower than
74% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. TECH: 2.12 )
Ranked among companies with meaningful Quick Ratio only.
TECH' s Quick Ratio Range Over the Past 10 Years
Min: 1.95  Med: 7.39 Max: 16.31
Current: 2.12
1.95
16.31
Days Inventory 123.03
TECH's Days Inventory is ranked higher than
54% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. TECH: 123.03 )
Ranked among companies with meaningful Days Inventory only.
TECH' s Days Inventory Range Over the Past 10 Years
Min: 63.05  Med: 116.73 Max: 192.76
Current: 123.03
63.05
192.76
Days Sales Outstanding 75.74
TECH's Days Sales Outstanding is ranked lower than
59% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. TECH: 75.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
TECH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.81  Med: 45.11 Max: 75.74
Current: 75.74
40.81
75.74
Days Payable 32.65
TECH's Days Payable is ranked lower than
75% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. TECH: 32.65 )
Ranked among companies with meaningful Days Payable only.
TECH' s Days Payable Range Over the Past 10 Years
Min: 28.64  Med: 33.49 Max: 46.43
Current: 32.65
28.64
46.43

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.05
TECH's Dividend Yield % is ranked lower than
56% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. TECH: 1.05 )
Ranked among companies with meaningful Dividend Yield % only.
TECH' s Dividend Yield % Range Over the Past 10 Years
Min: 0.39  Med: 1.39 Max: 1.82
Current: 1.05
0.39
1.82
Dividend Payout Ratio 0.63
TECH's Dividend Payout Ratio is ranked lower than
72% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. TECH: 0.63 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TECH' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.39 Max: 0.63
Current: 0.63
0.27
0.63
3-Year Dividend Growth Rate 1.30
TECH's 3-Year Dividend Growth Rate is ranked lower than
64% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. TECH: 1.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TECH' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 14
Current: 1.3
0
14
Forward Dividend Yield % 1.05
TECH's Forward Dividend Yield % is ranked lower than
54% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.26 vs. TECH: 1.05 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.21
TECH's 5-Year Yield-on-Cost % is ranked lower than
54% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. TECH: 1.21 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TECH' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.45  Med: 1.6 Max: 2.1
Current: 1.21
0.45
2.1
3-Year Average Share Buyback Ratio -0.30
TECH's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. TECH: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TECH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.6  Med: -0.3 Max: 2.4
Current: -0.3
-5.6
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.97
TECH's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
67% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. TECH: 1.97 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TECH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.28  Med: 2.03 Max: 12.77
Current: 1.97
1.28
12.77
Price-to-Intrinsic-Value-DCF (Earnings Based) 5.61
TECH's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
88% of the 26 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. TECH: 5.61 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
TECH' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.69  Med: 1.07 Max: 5.41
Current: 5.61
0.69
5.41
Price-to-Median-PS-Value 0.93
TECH's Price-to-Median-PS-Value is ranked higher than
54% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. TECH: 0.93 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TECH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 0.95 Max: 2.99
Current: 0.93
0.16
2.99
Earnings Yield (Greenblatt) % 2.55
TECH's Earnings Yield (Greenblatt) % is ranked higher than
80% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. TECH: 2.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TECH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.5  Med: 5.8 Max: 9.6
Current: 2.55
2.5
9.6
Forward Rate of Return (Yacktman) % 3.26
TECH's Forward Rate of Return (Yacktman) % is ranked lower than
71% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. TECH: 3.26 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TECH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.2  Med: 11.35 Max: 25.8
Current: 3.26
3.2
25.8

More Statistics

Revenue (TTM) (Mil) $563.00
EPS (TTM) $ 2.03
Beta0.85
Short Percentage of Float4.40%
52-Week Range $95.68 - 124.00
Shares Outstanding (Mil)37.39

Analyst Estimate

Jun18 Jun19 Jun20
Revenue (Mil $) 622 670 722
EPS ($) 4.11 4.48 4.87
EPS without NRI ($) 4.11 4.48 4.87
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 1.31 1.33 1.40
» More Articles for TECH

Headlines

Articles On GuruFocus.com
Bio-Techne Introduces a New Luminex Multi-analyte Assay Kit Sep 13 2017 
Bio-Techne Releases A Highly Sensitive and Specific Serological Assay to Detect Zika Virus Infection Sep 06 2017 
Bio-Techne Acquires Trevigen Inc. Sep 05 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bio-Techne Corpo Aug 30 2017 
Bio-Techne To Present At The Wells Fargo Healthcare Conference Aug 28 2017 
Bio-Techne To Present At The Baird 2017 Global Healthcare Conference Aug 22 2017 
Bio-Techne Declares Dividend Aug 10 2017 
Bio-Techne Releases Fourth Quarter Fiscal 2017 Results Aug 08 2017 
Bio-Techne To Host Conference Call On August 8, 2017 To Announce Fourth Quarter Financial Results Jul 12 2017 
Bio-Techne To Present At The Jefferies 2017 Global Healthcare Conference May 24 2017 

More From Other Websites
See what the IHS Markit Score report has to say about Bio-Techne Corp. Sep 15 2017
ETFs with exposure to Bio-Techne Corp. : September 14, 2017 Sep 13 2017
Bio-Techne Introduces a New Luminex Multi-analyte Assay Kit Sep 13 2017
Bio-Techne Corp. :TECH-US: Earnings Analysis: 2017 By the Numbers : September 11, 2017 Sep 11 2017
Featured Company News - Bio-Techne Acquires Trevigen in an All-cash Deal Sep 08 2017
Bio-Techne Releases A Highly Sensitive and Specific Serological Assay to Detect Zika Virus... Sep 06 2017
Bio-Techne Acquires Trevigen Inc. Sep 05 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bio-Techne... Aug 30 2017
Bio-Techne To Present At The Wells Fargo Healthcare Conference Aug 28 2017
Bio-Techne To Present At The Baird 2017 Global Healthcare Conference Aug 22 2017
Bio-Techne Corp. – Value Analysis (NASDAQ:TECH) : August 19, 2017 Aug 18 2017
Google's Alphabet passes Facebook as hedge fund favorite Aug 18 2017
Corporate News Blog - Exelixis Submits US Supplemental New Drug Application for CABOMETYX(R) for the... Aug 18 2017
Edited Transcript of TECH earnings conference call or presentation 8-Aug-17 1:00pm GMT Aug 16 2017
Bio-Techne Declares Dividend Aug 10 2017
Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4 Aug 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}